Overview An Early Phase 2 Clinical Study of KSP-0243 Status: Not yet recruiting Trial end date: 2025-03-01 Target enrollment: Participant gender: Summary A phase 2a, randomized, double-blind, placebo-controlled, multicenter, parallel-group study to administer KSP-0243 or a placebo once daily after breakfast for 8 weeks in 100 patients with mild to moderate active ulcerative colitis. Phase: Phase 2 Details Lead Sponsor: Kissei Pharmaceutical Co., Ltd.